Literature DB >> 9607788

Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats.

M I López-Delgado1, M Morales, M L Villanueva-Peñacarrillo, W J Malaisse, I Valverde.   

Abstract

Glucagon-like peptide 1(7-36)amide (GLP-1) is currently under investigation as a possible tool in the treatment of non-insulin-dependent diabetes mellitus. In addition to enhancing nutrient-stimulated insulin release, the peptide also favors glycogen synthesis and glucose use in liver, muscle, and adipose tissue. GLP-1 also activates glycogen synthase a in hepatocytes from both normal and diabetic rats. In the present study, the kinetic aspects of such an activation were investigated in hepatocytes from normal rats and from animals rendered diabetic induced by injection of streptozotocin, either in the adult age (insulin-dependent diabetes mellitus model) or in days 1 or 5 after birth (non-insulin-dependent diabetes mellitus models). GLP-1 increased, in a dose-dependent manner, glycogen synthase a activity in the hepatocytes from all groups studied. The activation of the enzyme reached a steady state within 1 min exposure to GLP-1, which, at 10(-12) M, caused a half-maximal activation. When comparing fed vs. overnight-starved normal rats, a somewhat lower basal activity of glycogen synthase a in fasted animals (P < 0.05) coincided with a greater relative increment in reaction velocity in response to GLP-1. The basal activity of glycogen synthase a and the relative extent of its inhibition by glucagon or activation by insulin and GLP-1 were modulated by the extracellular concentration of D-glucose. The activation of glycogen synthase a by either insulin or GLP-1 resulted not solely in an increase in maximal velocity but also in a decrease in affinity of the enzyme for uridine diphosphate-glucose; in diabetic animals, the capacity of insulin or GLP-1 to increase the maximal velocity and Michaelis-Menten constant were less marked than in normal rats. In conclusion, this study indicates that the GLP-1-induced activation of glycogen synthase a displays attributes of rapidity, sensitivity, and nutritional dependency that are well suited for both participation in the physiological regulation of enzyme activity and therapeutic purpose.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607788     DOI: 10.1210/endo.139.6.6045

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.

Authors:  Xiaokun Ding; Neeraj K Saxena; Songbai Lin; Nitika Arora Gupta; Narita Gupta; Frank A Anania
Journal:  Hepatology       Date:  2006-01       Impact factor: 17.425

2.  Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells.

Authors:  Alice Y Chen-Liaw; Gabrielle Hammel; George Gomez
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-07-13       Impact factor: 2.416

3.  Potentiation and prolongation of the insulinotropic action of glucagon-like peptide 1 by methyl pyruvate or dimethyl ester of L-glutamic acid in a type 2 diabetes animal model.

Authors:  J Cancelas; M L Villanueva-Peñacarrillo; I Valverde; W J Malaisse
Journal:  Endocrine       Date:  2001-11       Impact factor: 3.633

Review 4.  Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.

Authors:  Claire M Issa; Sami T Azar
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

Review 5.  Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides.

Authors:  Rania Abu-Hamdah; Atoosa Rabiee; Graydon S Meneilly; Richard P Shannon; Dana K Andersen; Dariush Elahi
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

Review 6.  Oxidative Stress, Intrauterine Growth Restriction, and Developmental Programming of Type 2 Diabetes.

Authors:  Cetewayo S Rashid; Amita Bansal; Rebecca A Simmons
Journal:  Physiology (Bethesda)       Date:  2018-09-01

7.  GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation.

Authors:  Makoto Shigeto; Reshma Ramracheya; Andrei I Tarasov; Chae Young Cha; Margarita V Chibalina; Benoit Hastoy; Koenraad Philippaert; Thomas Reinbothe; Nils Rorsman; Albert Salehi; William R Sones; Elisa Vergari; Cathryn Weston; Julia Gorelik; Masashi Katsura; Viacheslav O Nikolaev; Rudi Vennekens; Manuela Zaccolo; Antony Galione; Paul R V Johnson; Kohei Kaku; Graham Ladds; Patrik Rorsman
Journal:  J Clin Invest       Date:  2015-11-16       Impact factor: 14.808

8.  Dipeptidylpeptidase--IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats.

Authors:  E Tarantola; V Bertone; G Milanesi; E Capelli; A Ferrigno; D Neri; M Vairetti; S Barni; I Freitas
Journal:  Eur J Histochem       Date:  2012-10-08       Impact factor: 3.188

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.